Mansouri Alireza, Larjani Soroush, Klironomos George, Laperriere Normand, Cusimano Michael, Gentili Fred, Schwartz Michael, Zadeh Gelareh
Division of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto;
Division of Neurosurgery, University of Toronto;
J Neurosurg. 2015 Nov;123(5):1294-300. doi: 10.3171/2014.12.JNS141687. Epub 2015 Jul 3.
In this paper, the authors' aim was to determine short-term volumetric and diametric tumor growth and identify clinical, radiological, and dosimetric predictors of adverse radiation events (AREs) following stereotactic radiosurgery (SRS) for intracranial WHO Grade I meningiomas.
This is a retrospective review of all WHO Grade I meningiomas that were treated with SRS (primary or adjuvant) between December 2005 and June 2012 at the University Health Network. Seventy-five patients had at least 24 months of both clinical and radiological follow-up and were, therefore, included in this study. Tumor growth was defined as any volumetric or diametric change greater than 10% per year. Any variation less than +10% was considered growth stability. Volumetric measurements were made using T1-weighted gadolinium-enhanced 3-T MRI scans and ITK-SNAP software. Tumor growth rates were calculated using the specific growth rate (SGR). Univariate statistics were used to identify predictors of post-SRS AREs. All statistical analyses were performed using IBM SPSS.
Women accounted for 69.3% of patients, and the mean treatment age was 58.6 years. Median follow-up was 36.2 months. Twenty-one (28%) patients had undergone prior resection. Two (3%) patients required salvage surgical intervention following SRS. The majority of the lesions (56%) were skull base tumors. Median tumor volume and diameter were 5.2 cm3 and 27.5 mm, respectively. The absence of tumor growth was observed in 39 cases (52%) based on the volumetric measurements, while the absence of tumor growth was observed in 69 cases (92%) based on the diametric measurements. Twenty-six patients (34.6%) experienced new-onset AREs, including headache (17.3%), cranial neuropathy (10.6%), speech impairment (2.7%), tremors (2.7%), and ataxia (1.3%). Fourteen patients (18.7%) experienced new-onset edema, and 4 of these patients were symptomatic. A lower conformity index (1.24 vs 1.4) was significantly associated with the development of edema (p<0.001 power>0.8). Patients with meningiomas that had growth rates of more than 10% per year were more likely to experience long-term headaches after SRS (p=0.022).
Volume-based reporting of SRS outcomes for meningiomas may be a more accurate method given the complex morphology of some lesions. The conformity index was identified as a predictor of edema following radiosurgery.
在本文中,作者的目的是确定颅内世界卫生组织(WHO)I级脑膜瘤立体定向放射外科治疗(SRS)后肿瘤的短期体积和直径生长情况,并识别不良放射事件(ARE)的临床、放射学和剂量学预测因素。
这是一项对2005年12月至2012年6月在大学健康网络接受SRS(原发性或辅助性)治疗的所有WHO I级脑膜瘤的回顾性研究。75例患者至少有24个月的临床和放射学随访,因此被纳入本研究。肿瘤生长定义为每年体积或直径变化大于10%。任何小于+10%的变化被视为生长稳定。使用T1加权钆增强3-T MRI扫描和ITK-SNAP软件进行体积测量。使用特定生长率(SGR)计算肿瘤生长率。采用单变量统计来识别SRS后ARE的预测因素。所有统计分析均使用IBM SPSS进行。
女性占患者的69.3%,平均治疗年龄为58.6岁。中位随访时间为36.2个月。21例(28%)患者曾接受过手术切除。2例(3%)患者在SRS后需要挽救性手术干预。大多数病变(56%)为颅底肿瘤。肿瘤中位体积和直径分别为5.2 cm³和27.5 mm。根据体积测量,39例(52%)未观察到肿瘤生长,而根据直径测量,69例(92%)未观察到肿瘤生长。26例(34.6%)患者出现新发ARE,包括头痛(17.3%)、颅神经病变(10.6%)、言语障碍(2.7%)、震颤(2.7%)和共济失调(1.3%)。14例(18.7%)患者出现新发水肿,其中4例有症状。较低的适形指数(1.24对1.4)与水肿的发生显著相关(p<0.001,检验效能>0.8)。每年生长率超过10%的脑膜瘤患者在SRS后更有可能出现长期头痛(p=0.022)。
鉴于某些病变的复杂形态,基于体积报告脑膜瘤的SRS结果可能是一种更准确的方法。适形指数被确定为放射外科治疗后水肿的预测因素。